T
Todd R. Golub
Researcher at Harvard University
Publications - 454
Citations - 234100
Todd R. Golub is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Gene expression profiling. The author has an hindex of 164, co-authored 422 publications receiving 201457 citations. Previous affiliations of Todd R. Golub include Rush University Medical Center & Boston Children's Hospital.
Papers
More filters
Patent
Genetic markers for tumors
TL;DR: In this paper, sets of genetic markers for specific tumor classes are described, as well as methods of identifying a biological sample based on these markers, including diagnostic, prognostic, and therapeutic screening uses for these markers.
Journal ArticleDOI
A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response
Ryan J. Sullivan,Yujin Hoshida,Jean-Philippe Brunet,Steven R. Tahan,Julie Aldridge,C. Kwabi,E. Gardiner,David F. McDermott,Todd R. Golub,Michael B. Atkins +9 more
TL;DR: The overall and CR rates in a contemporary series of pts with metastatic melanoma treated with HD IL-2 are twice that reported in initial studies suggesting some treatment selection on clinical grounds since the 1990s.
Posted ContentDOI
Non-oncology drugs are a source of previously unappreciated anti-cancer activity
Steven M. Corsello,Steven M. Corsello,Rohith T. Nagari,Ryan Spangler,Jordan Rossen,Mustafa Kocak,Jordan Bryan,Ranad Humeidi,David Peck,Xiaoyun Wu,Anna Tang,Vickie M. Wang,Sam Bender,Evan Lemire,Rajiv Narayan,Philip Montgomery,Uri Ben-David,Yii-Der Ida Chen,Matthew G. Rees,Nicholas J. Lyons,James M. McFarland,Bang Wong,Li Wang,Nancy Dumont,Patrick O'Hearn,Eric Stefan,John G. Doench,Heidi Greulich,Matthew Meyerson,Matthew Meyerson,Francisca Vazquez,Ayshwarya Subramanian,Jennifer Roth,Joshua Bittker,Jesse S. Boehm,Christopher C. Mader,Aviad Tsherniak,Todd R. Golub +37 more
TL;DR: The results illustrate the potential of the PRISM drug repurposing resource as a starting point for new oncology therapeutic development and relative barcode abundance following treatment thus reflects cell line viability.
Journal ArticleDOI
A Functional Screen Identifies miRs That Induce Radioresistance in Glioblastomas
Patryk Moskwa,Patryk Moskwa,Pascal O. Zinn,Young Eun Choi,Sachet A. Shukla,Sachet A. Shukla,Wojciech Fendler,Clark C. Chen,Jun Lu,Todd R. Golub,Todd R. Golub,Todd R. Golub,Anita B. Hjelmeland,Dipanjan Chowdhury +13 more
TL;DR: Together, these results identify and characterize a new role for miR425, miR1,miR125, and miR150 in promoting radioresistance in glioblastomas and provide insight into the therapeutic application of TGFβ inhibitors in radiotherapy.
Journal ArticleDOI
Tel gene rearrangements in myeloid malignancy
TL;DR: It is conceivable that the TEL gene is the common target for various translocations precisely because of this pleiotropy of pathogenic mechanisms by which Tel gene rearrangements can lead to cell transformation.